Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

placebo combined with chemotherapy

Preclinical

SShandong New Time Pharmaceutical Co., LTD

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cancer of Unknown Primary SiteRecruiting

Cancer of Unknown Primary SitePreclinical

Recruiting

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Stomach Neoplasms

NCT06576921

Q2 2028

PreclinicalRecruiting

Cancer of Unknown Primary Site

NCT07761429

Clinical

Trials by Indication[1]

Stomach Neoplasms1 trial

Efficacy and Safety of Serplulimab Combined With Nab-paclitaxel and SOX as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction: A Multicenter Randomized Controlled Trial

Active, not recruiting·XXijing Hospital·Phase 2·NCT06576921·116 enrolled

Cancer of Unknown Primary Site1 trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Study Evaluating the Safety and Efficacy of F520 Combined With Paclitaxel Plus Carboplatin as First-line Treatment for Cancer of Unknown Primary

Recruiting·SShandong New Time Pharmaceutical Co., LTD·Preclinical·NCT07761429·402 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for placebo combined with chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for placebo combined with chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shandong New Time Pharmaceutical Co., LTD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShandong New Time Pharmaceutical Co., LTD

Related News